OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study
Xiaohong Fan, Xiahong Dai, Yun Ling, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 2, pp. 129-139
Closed Access | Times Cited: 27
Xiaohong Fan, Xiahong Dai, Yun Ling, et al.
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 2, pp. 129-139
Closed Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
SARS-CoV-2 Drug Resistance and Therapeutic Approaches
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Sania Batool, Santosh Chokkakula, Ju Hwan Jeong, et al.
Heliyon (2025) Vol. 11, Iss. 2, pp. e41980-e41980
Open Access | Times Cited: 3
Treating Acute Covid-19 — Final Chapters Still Unwritten
Rajesh T. Gandhi, Martin Hirsch
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1234-1236
Open Access | Times Cited: 14
Rajesh T. Gandhi, Martin Hirsch
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1234-1236
Open Access | Times Cited: 14
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 13
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 13
Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Y.-C. Chung, Ching-Yin Lam, Pak-Hei Tan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8155-8155
Open Access | Times Cited: 10
Y.-C. Chung, Ching-Yin Lam, Pak-Hei Tan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8155-8155
Open Access | Times Cited: 10
The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants
Aleksandr Ianevski, Irene Trøen Frøysa, Hilde Lysvand, et al.
Antiviral Research (2024) Vol. 224, pp. 105842-105842
Open Access | Times Cited: 9
Aleksandr Ianevski, Irene Trøen Frøysa, Hilde Lysvand, et al.
Antiviral Research (2024) Vol. 224, pp. 105842-105842
Open Access | Times Cited: 9
Application of deuterium in research and development of drugs
Jiong Chen, Yuan‐Yuan Zhu, Lu Huang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117371-117371
Closed Access | Times Cited: 1
Jiong Chen, Yuan‐Yuan Zhu, Lu Huang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 287, pp. 117371-117371
Closed Access | Times Cited: 1
Dose determination of VV116 in COVID-19 patients with severe liver dysfunction: a case report
Jing Yang, Wenwen Jiang, Jianqing Deng, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access | Times Cited: 1
Jing Yang, Wenwen Jiang, Jianqing Deng, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access | Times Cited: 1
Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial
Hongzhou Lu, George Zhang, John Mao, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102582-102582
Open Access | Times Cited: 8
Hongzhou Lu, George Zhang, John Mao, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102582-102582
Open Access | Times Cited: 8
Recent Progress toward the Discovery of Small Molecules as Novel Anti-Respiratory Syncytial Virus Agents
Tommaso Felicetti, Chiara Sarnari, Roberta Gaito, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 8
Tommaso Felicetti, Chiara Sarnari, Roberta Gaito, et al.
Journal of Medicinal Chemistry (2024)
Closed Access | Times Cited: 8
Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV
Ellen Bowden-Reid, Ernest Moles, Anthony D. Kelleher, et al.
Drug Delivery and Translational Research (2025)
Open Access
Ellen Bowden-Reid, Ernest Moles, Anthony D. Kelleher, et al.
Drug Delivery and Translational Research (2025)
Open Access
Synergistic combination of orally available safe-in-man pleconaril, AG7404, and mindeudesivir inhibits enterovirus infections in human cell and organoid cultures
Erlend Ravlo, Aleksandr Ianevski, Jørn-Ove Schjølberg, et al.
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
Erlend Ravlo, Aleksandr Ianevski, Jørn-Ove Schjølberg, et al.
Cellular and Molecular Life Sciences (2025) Vol. 82, Iss. 1
Open Access
Pharmacokinetics, Mass Balance, Safety, and Tolerability of Obeldesivir in Healthy Participants
Olena Anoshchenko, Mazin Abdelghany, Amos Lichtman, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 5, pp. 1231-1239
Open Access | Times Cited: 3
Olena Anoshchenko, Mazin Abdelghany, Amos Lichtman, et al.
Clinical Pharmacology & Therapeutics (2024) Vol. 116, Iss. 5, pp. 1231-1239
Open Access | Times Cited: 3
Development of antiviral drugs for COVID-19 in 2025: unmet needs and future challenges
Daniele Focosi, David J. Sullivan, Massimo Franchini
Expert Review of Anti-infective Therapy (2025)
Closed Access
Daniele Focosi, David J. Sullivan, Massimo Franchini
Expert Review of Anti-infective Therapy (2025)
Closed Access
Antivirals in COVID‐19: A Focus on Pediatric Cardiac Patients
Darsh Safi, Farah Khouri, Rana Zareef, et al.
Canadian Journal of Infectious Diseases and Medical Microbiology (2025) Vol. 2025, Iss. 1
Open Access
Darsh Safi, Farah Khouri, Rana Zareef, et al.
Canadian Journal of Infectious Diseases and Medical Microbiology (2025) Vol. 2025, Iss. 1
Open Access
Discovery and Development of VV116: A Novel Oral Nucleoside Anti‐SARS‐CoV‐2 Drug
(2025), pp. 389-410
Closed Access
(2025), pp. 389-410
Closed Access
Superior Antiviral Efficacy of Combined 3CL Protease and RdRp Inhibition Compared to 3CL Protease Inhibitor Monotherapy in Hospitalized COVID-19 Patients
Yuan Gao, Jiaying Zhang, Muxin Liu, et al.
Journal of Infection (2025), pp. 106502-106502
Open Access
Yuan Gao, Jiaying Zhang, Muxin Liu, et al.
Journal of Infection (2025), pp. 106502-106502
Open Access
Structural review of SARS-CoV-2 antiviral targets
Wen Cui, Yinkai Duan, Gao Yan, et al.
Structure (2024) Vol. 32, Iss. 9, pp. 1301-1321
Closed Access | Times Cited: 3
Wen Cui, Yinkai Duan, Gao Yan, et al.
Structure (2024) Vol. 32, Iss. 9, pp. 1301-1321
Closed Access | Times Cited: 3
Surrogate Endpoints in Pandemic Preparedness
Harm‐Jan de Grooth, Jean‐Jacques Parienti
The Journal of Infectious Diseases (2024) Vol. 229, Iss. 4, pp. 1244-1245
Open Access | Times Cited: 2
Harm‐Jan de Grooth, Jean‐Jacques Parienti
The Journal of Infectious Diseases (2024) Vol. 229, Iss. 4, pp. 1244-1245
Open Access | Times Cited: 2
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19
Kanal Singh, Joseph M. Rocco, Véronique Nussenblatt
Seminars in Hematology (2024) Vol. 61, Iss. 5, pp. 321-332
Closed Access | Times Cited: 2
Kanal Singh, Joseph M. Rocco, Véronique Nussenblatt
Seminars in Hematology (2024) Vol. 61, Iss. 5, pp. 321-332
Closed Access | Times Cited: 2
Oral and intravenous 1'-cyano-substituted adenosine-like antivirals for early COVID-19
Robert Gottlieb, Roger Paredes
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 2, pp. 108-110
Open Access | Times Cited: 4
Robert Gottlieb, Roger Paredes
The Lancet Infectious Diseases (2023) Vol. 24, Iss. 2, pp. 108-110
Open Access | Times Cited: 4
Nirmatrelvir for Adult Outpatients with Covid-19
Dan Shan, Guangji Zhang, Zhongyan Du
New England Journal of Medicine (2024) Vol. 391, Iss. 5, pp. 477-479
Open Access | Times Cited: 1
Dan Shan, Guangji Zhang, Zhongyan Du
New England Journal of Medicine (2024) Vol. 391, Iss. 5, pp. 477-479
Open Access | Times Cited: 1
Combating Emerging Respiratory Viruses: Lessons and Future Antiviral Strategies
Palaniyandi Muthukutty, Jaime MacDonald, So Young Yoo
Vaccines (2024) Vol. 12, Iss. 11, pp. 1220-1220
Open Access | Times Cited: 1
Palaniyandi Muthukutty, Jaime MacDonald, So Young Yoo
Vaccines (2024) Vol. 12, Iss. 11, pp. 1220-1220
Open Access | Times Cited: 1
Targeting viral suppressor of RNAi confers anti-coronaviral activity
Jiyao Chen, Jingfang Mu, Kangping Zhou, et al.
Molecular Therapy (2024)
Closed Access | Times Cited: 1
Jiyao Chen, Jingfang Mu, Kangping Zhou, et al.
Molecular Therapy (2024)
Closed Access | Times Cited: 1
The treatment of COVID-19: lessons learned and future directions
Michael Cenname, Matthew W. McCarthy
Future Virology (2024) Vol. 19, Iss. 8-9, pp. 315-323
Closed Access
Michael Cenname, Matthew W. McCarthy
Future Virology (2024) Vol. 19, Iss. 8-9, pp. 315-323
Closed Access
Antiviral therapy for COVID-19
Adamantia Liapikou, Μαρία Λερίκου
European Respiratory Society eBooks (2024)
Closed Access
Adamantia Liapikou, Μαρία Λερίκου
European Respiratory Society eBooks (2024)
Closed Access
